Literature DB >> 16569887

Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.

William R Kirkpatrick1, Brent J Coco, Thomas F Patterson.   

Abstract

We evaluated combinations of voriconazole (VRC) and liposomal amphotericin B (L-AMB) in a guinea pig invasive aspergillosis model. Simultaneous VRC and L-AMB was most effective, although VRC monotherapy was also effective. These regimens as well as sequential L-AMB followed by VRC were more effective than L-AMB alone or VRC followed by L-AMB.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16569887      PMCID： PMC1426916          DOI： 10.1128/AAC.50.4.1567-1569.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 2.  Combination antifungal therapy.

Authors:  Thomas F Patterson
Journal:  Pediatr Infect Dis J       Date:  2003-06       Impact factor: 2.129

3.  Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

4.  Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy.

Authors:  D P Kontoyiannis; R E Lewis; N Sagar; G May; R A Prince; K V Rolston
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

6.  Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.

Authors:  T F Patterson; W R Kirkpatrick; M White; J W Hiemenz; J R Wingard; B Dupont; M G Rinaldi; D A Stevens; J R Graybill
Journal:  Medicine (Baltimore)       Date:  2000-07       Impact factor: 1.889

Review 7.  Aspergillosis case-fatality rate: systematic review of the literature.

Authors:  S J Lin; J Schranz; S M Teutsch
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

8.  Combination antifungal therapy for invasive aspergillosis.

Authors:  Kieren A Marr; Michael Boeckh; Rachel A Carter; Hyung Woo Kim; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2004-08-27       Impact factor: 9.079

9.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Authors:  John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

10.  Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism.

Authors:  A Schaffner; A Böhler
Journal:  Mycoses       Date:  1993 Nov-Dec       Impact factor: 4.377
View more
  11 in total

1.  Use of Antifungal Combination Therapy: Agents, Order, and Timing.

Authors:  Melissa D Johnson; John R Perfect
Journal:  Curr Fungal Infect Rep       Date:  2010-05-01

Review 2.  Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.

Authors:  Alice J Hsu; Pranita D Tamma; Brian T Fisher
Journal:  Antimicrob Agents Chemother       Date:  2022-06-29       Impact factor: 5.938

3.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

4.  Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture.

Authors:  Ana C Vallor; William R Kirkpatrick; Laura K Najvar; Rosie Bocanegra; Marsha C Kinney; Annette W Fothergill; Monica L Herrera; Brian L Wickes; John R Graybill; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

Review 5.  Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.

Authors:  Neil R H Stone; Tihana Bicanic; Rahuman Salim; William Hope
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 6.  Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Front Microbiol       Date:  2017-05-16       Impact factor: 5.640

7.  Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia.

Authors:  Kyu Ho Lee; Young Tae Lim; Jeong Ok Hah; Yu Kyung Kim; Chae Hoon Lee; Jae Min Lee
Journal:  Blood Res       Date:  2017-09-25

8.  Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series.

Authors:  Anna Maria Peri; Marta Verna; Stefano Biffi; Laura Alagna; Benedetta Longhi; Guglielmo Marco Migliorino; Sergio Foresti; Alessandra Bandera; Attilio Rovelli; Carmelo Rizzari; Andrea Gori; Antonella Colombini
Journal:  Pathog Immun       Date:  2019-09-05

Review 9.  Optimizing efficacy of Amphotericin B through nanomodification.

Authors:  Gillian Barratt; Stéphane Bretagne
Journal:  Int J Nanomedicine       Date:  2007

Review 10.  Animal models: an important tool in mycology.

Authors:  Javier Capilla; Karl V Clemons; David A Stevens
Journal:  Med Mycol       Date:  2007-12       Impact factor: 4.076
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.